Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$0.70 USD
+0.01 (1.05%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $0.71 +0.01 (0.95%) 4:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CUE 0.70 +0.01(1.05%)
Will CUE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CUE
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
CUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
Other News for CUE
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
Central Petroleum Secures Key Gas Sale Agreement
Cue Energy Announces Expansion of Indonesia Oil Field
Cue Energy Expands Oil Production in Indonesia
Central Petroleum Extends Arafura Gas Agreement Deadline